Posted by AGORACOM-JC
at 7:21 AM on Thursday, December 3rd, 2020
Announced that the Company is in receipt of advisory services and up to $500,000 in research and development funding from National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to complete final commercialization and mass production requirements for its Covid-19 technology, the Kontrol BioCloudTM analyzer
Company has commenced initial production of BioCloud units for delivery in approximately 5 to 6 weeks. Initial deliveries include the sale of units to distributors and Kontrol customers.
Further, the Company will deliver demonstration units to pilot customers in the Middle East.
TORONTO, ON / December 3, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to announce that the Company is in receipt of advisory services and up to $500,000 in research and development funding from National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to complete final commercialization and mass production requirements for its Covid-19 technology, the Kontrol BioCloudTM analyzer (“BioCloud analyzer” or “BioCloud“).
“This is another important accomplishment and milestone for Kontrol and represents the continuing advancement of the BioCloud technology,” says Paul Ghezzi, CEO Kontrol. “The focus of our BioCloud technology is to help create safe spaces for all as we collectively continue to face the challenge of the COVID-19 pandemic. We are thankful for this support from NRC IRAP.”
Production
The Company has commenced initial production of BioCloud units for delivery in approximately 5 to 6 weeks. Initial deliveries include the sale of units to distributors and Kontrol customers. Further, the Company will deliver demonstration units to pilot customers in the Middle East. The Company will announce those sales which are material and other sales will be reported in the applicable quarterly financial statements as ordinary course.
About Kontrol BioCloudTM
BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, offices, retirement homes, hospitals, mass transportation and others.
Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com
BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus). Safe Space Technology is a Kontrol Trademark.
About Kontrol Energy
Kontrol Energy Corp., a Canadian public company, is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol Energy provides a combination of software, hardware, and service solutions to its customers to improve energy management, air quality and continuous emission monitoring.
Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com
Posted by AGORACOM-JC
at 7:35 AM on Wednesday, December 2nd, 2020
Announced that Kai Medical Laboratory (“KAI”) will be launching an FDA approved, at home/work saliva COVID-19 RT-PCR test (“Saliva Test”) on December 15th.
In addition, the Company’s previously announced KAI ABC-PCR test protocol to simultaneously differentiate between Influenza A/B and COVID-19 (“ABC”), will be launching on December 7th, with our record film & tv production contract switching to KAI ABC PCR and increasing the number of test units to 10,000.
VANCOUVER, BC / December 2, 2020 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving a database of 165,000 patients through clinics in the southwest United States, a telemedicine platform and medical diagnostics laboratory, is pleased to announce that Kai Medical Laboratory (“KAI”) will be launching an FDA approved, at home/work saliva COVID-19 RT-PCR test (“Saliva Test”) on December 15th.
In addition, the Company’s previously announced KAI ABC-PCR test protocol to simultaneously differentiate between Influenza A/B and COVID-19 (“ABC”), will be launching on December 7th, with our record film & tv production contract switching to KAI ABC PCR and increasing the number of test units to 10,000.
FDA APPROVED “SPIT AND SHAKE” AT HOME/WORK SALIVA TEST IS A GAME CHANGER
The KAI Saliva Test is the direct result of investing in scientific R&D through KAI, empowering them to deliver clinical trial data and validation. This gives Empower a strong upper hand nationally and now potentially on an international stage.
The power of the Saliva Test is in its simplicity, in which users merely spit into a funnel, then close the funnel with a lid containing a liquid to be mixed with the saliva by simply shaking it for 5 seconds. This saliva based PCR test does not require a medical technician to administer the specimen collection which can be done by the individual, a parent or an administrator. The specimen is returned to KAI Medical Labs from anywhere in the country for processing. KAI will analyze and provide a response within 24 hours through its HIPAA compliant IT system.
Empower Clinics CEO, Steven McAuley stated “The new KAI Saliva Test is an anywhere-based PCR test that is non-invasive and can even be used to test children. It’s simple, effective and can be distributed nationwide with FDA approval using the KAI assay and processing procedures. It is a game changer in its simplicity and we are optimistic about its success.”
The KAI Saliva Test will be available for sale December 15th, with distribution expected to comprise of online access, wholesale programs and available through our clinic group Sun Valley Health.
KAI ABC RT-PCR TEST PROTOCOL TO DIFFERENTIATE BETWEEN INFLUENZA A/B AND COVID-19 (“ABC”) LAUNCHES WITH RECORD ORDER FROM FILM & TV PRODUCTION
LAUNCH DATE OF COVID-19 ABC RT-PCR TEST MAKES KAI A LEADING NATIONAL MEDICAL LABORATORY
Given the fact that household named labs have not been able to begin distributing their form of an ABC PCR test, the KAI launch date and record order for its ABC RT-PCR test makes KAI Medical Labs a national leader in COVID-19 testing. As a result, Empower has filed a trademark for KAI ABC PCR.
Empower CEO McAuley added “The requirements for more diverse and flexible testing protocols solving complex operational requirements for consumers, industry, private and public sectors form the scientific R&D focus for KAI Medical, as we lead trials and validation for the latest COVID-19 tests.”
Having these new simplified and highly accurate “gold standard” RT-PCR tests opens up markets by breaking down barriers to enable industries to get back to business again, while enabling the public sector to deliver the services of the government that countries depend upon.
MULTIPLE BENEFITS OF KAI ABC RT-PCR RANGE FROM EARLY AND CORRECT DIAGNOSIS TO PACKAGED COST SAVINGS
COVID-19 and influenza viruses have a similar disease presentation. They both cause respiratory disease, which presents as a wide range of illness from asymptomatic or mild through to severe disease and death. As such, the benefits of this KAI ABC PCR test protocol being able to differentiate between the Flu and COVID-19 are invaluable as follows:
First, it is vital in the diagnosis and treatment of respiratory pathogens. As most COVID-19 testing now primarily focuses on COVID-19 only, diagnosing the difference between the two will be crucial to treatment, health outcomes, and overall health of the population. Specifically, differentiating the pathogens will help medical professionals quickly diagnose and treat more efficiently & efficaciously.
Second, it is a vital tool in helping slow down the spread of COVID-19. Specifically, the speed of transmission is an important point of difference between the two viruses. Influenza has a shorter median incubation period (the time from infection to appearance of symptoms) than COVID-19. Transmission in the first 3-5 days of illness is a major driver for the spread of viral infections. This makes COVID-19 extremely difficult to contain. This is why testing to differentiate the viral infections becomes critical to “slowing the spread.”
Finally, affordability and efficiency. Though the overall cost of an ABC RT-PCR test is approximately 15% to 25% more expensive than an RT-PCR test, providing analysis on all three viruses is significantly cheaper and more affordable than testing for them separately. Moreover, from an efficiency point of view, simultaneously confirming a patient has the flu and does not have COVID-19 from the same collected specimen, allows them, their families and work colleagues to return to a normal life much faster.
BENEFITS TO EMPOWER CLINICS
From a business development point of view, Empower has a high degree of confidence the multiple benefits listed above will translate into significant new business, as evidenced already by the transition of the Company’s recent $1,000,000 test order by a film & tv production from RT-PCR to the new KAI ABC PCR protocol.
From an R&D perspective, Kai Medical Laboratory is focused on the future and new innovative quality testing to better understand the epidemiology and contagion containment that we have all experienced during this pandemic. Kai Medical will continue to be at the forefront of science and innovative quality care by providing value added services, accuracy, and consistency. As such, we believe more successful R&D product announcements will be made in the near future.
ABOUT EMPOWER
Empower is creating a network of physicians and practitioners who integrate to serve patient needs, in-clinic, through telemedicine, and with decentralized mobile delivery. A simplified, streamlined care model bringing key attributes of the healthcare supply chain together, always focused on patient experience. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative in the United States. Empower recently acquired Kai Medical Laboratory, LLC as a wholly owned subsidiary with large-scale testing capability.
This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.
Posted by AGORACOM-JC
at 4:24 PM on Tuesday, December 1st, 2020
Announced the appointment of Mr. Frank Carnevale as Chief Growth Officer.
Mr Carnevale is the former Chief Operating Officer of the Company, and is returning to focus on acquisitions, investments, organic growth strategies and execution to improve the overall value of the Company.
Mr. Carnevale will work closely with the CEO, Mr. Chris Hazelton, in delivering an aggressive growth program over the coming months.
Toronto, Ontario–(December 1, 2020) – Universal PropTech Inc. (TSXV: UPI) (“the Company”) is pleased to announce the appointment of Mr. Frank Carnevale as Chief Growth Officer.
Mr Carnevale is the former Chief Operating Officer of the Company, and is returning to focus on acquisitions, investments, organic growth strategies and execution to improve the overall value of the Company. Mr. Carnevale will work closely with the CEO, Mr. Chris Hazelton, in delivering an aggressive growth program over the coming months.
Mr. Carnevale is an award-winning CxO, industry thought leader, and has originated over $2.5 billion in energy transactions in regulated and unregulated energy service companies. He served as an Executive Board Member of the Energy Council of Canada from 2017 to 2019. He also served as a Board Member of the Council for Clean & Reliable Electricity, and the Ontario Energy Association.
“I see tremendous opportunities to improve the value of facilities by integrating proptech innovation with design, operations, and all in a very holistic customer-centric approach,” commented Frank Carnevale, Chief Growth Officer of Universal PropTech Inc.
“We are excited to have Frank back with us to aggressively grow our businesses,” stated Chris Hazelton, Chief Executive of Officer of Universal PropTech Inc. “He brings a unique perspective on how to take our share of the ongoing transformation in proptech and energy.”
About Universal PropTech Inc.
Universal PropTech Inc. (TSXV: UPI), conducts its operations through its wholly-owned subsidiary, VCI Controls Inc. (“VCI”), a leading supplier and integrator of proptech healthy building solutions and services. The Company is an industry leader in the development of intelligent building technology, including the integration of all building systems utilizing the latest in communications technologies and standards. VCI’s business focuses on digital controls and mechanical services, performance monitoring, and energy efficiency solutions.
With headquarters in Toronto, Universal PropTech has offices across Canada including, Halifax, Montreal, and Ottawa. For more information, visit www.universalproptech.com
Certain statements in this press release are forward-looking statements. The reader is cautioned that assumptions used in the preparation of such information, although considered reasonable by the Company at the time of preparation, may prove to be incorrect. Forward-looking statements, specifically those concerning future performance and other statements that are not historical fact, are subject to certain risks and uncertainties, and actual results may differ materially from the Company’s plans and expectations. These plans, expectations, risks and uncertainties are detailed herein and from time to time in the filings made by the Company with the TSX Venture Exchange (the “Exchange”) and securities regulators. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Trading in the securities of the Company should be considered highly speculative. All forward-looking information contained in this news release is expressly qualified in its entirety by this cautionary statement.
Neither the Exchange, nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
Posted by AGORACOM-JC
at 7:25 AM on Tuesday, December 1st, 2020
ImagineAR™ Elves Help Interactive 3D Santa Come into Homes Easily
Using the free ImagineAR™ app on their phones, parents can bring a life-sized talking 3D Santa directly from the North Pole into their living rooms for photos and videos.
NORTH POLE, Dec. 1, 2020 – ImagineAR Inc. (CSE: IP) (OTC: IPNFF) Santa Claus knows how important it is to keep children and families safe and healthy, so for the first time ever, he will enter homes of good little boys and girls via their parents’ smartphones, rather than chimneys. Using the free ImagineAR™ app on their phones, parents can bring a life-sized talking 3D Santa directly from the North Pole into their living rooms for photos and videos.
“Yes, it’s true,” said Santa. “The elves at ImagineAR and I wanted to bring some early holiday cheer to children this year, since social distancing has stopped my visits to shopping malls, stores and special events. We wanted to make sure children could still have their yearly photo with me and could even dance with me in their very own homes,” the jolly one said.
Inspired by the distraught 5-year old daughter of a fellow elf, ImagineAR head elf Alen Paul Silverrstieen and his team got to work. “This little girl wanted to visit Santa before the holidays and while she understood it wasn’t safe, it broke Santa’s heart,” said Silverrstieen. “The big guy was quite clear- make it so parents, grandparents and friends can use their smartphone to bring him directly into the homes of children everywhere for photos. We went a step further with Santa’s magic- using the free ImagineAR app and from the phone, folks can even record video of Santa Claus dancing with their little ones in front of their very own trees to share with family and friends!” he announced proudly.
To have Santa drop in to your home, just download the free ImagineAR app in the IOS App Store or Google Play on your mobile device, select “AR Near Me”, select your preferred Santa experience from the bottom of the screen, and Santa will magically appear right in front of you through your phone. The ImagineAR app has multiple Santa experiences to choose from. “In case a half-eaten cookie and empty glass of milk aren’t enough, we can even provide parents with photographic ‘proof’ that Santa was in their home on Christmas Eve stealthily with his big bag of toys,” whispered Silverrstieen.
“I’m an old guy, set in my ways,” chuckled Santa. “Don’t tell anyone, but I’ll likely still use chimneys, too. But my ImagineAR elves have really outdone themselves..Wishing everyone a very merry Christmas! Ho! Ho! Ho!”
About ImagineAR ImagineAR Inc. (CSE: IP) (OTC: IPNFF) is an augmented reality (AR) platform, ImagineAR.com, that enables businesses of any size to create and implement their own AR campaigns with no programming or technology experience. Every organization, from professional sports franchises to small retailers, can develop interactive AR campaigns that blend the real and digital worlds. Customers simply point their mobile device at logos, signs, buildings, products, landmarks and more to instantly engage videos, information, advertisements, coupons, 3D holograms and any interactive content all hosted in the cloud and managed using a menu-driven portal. Integrated real-time analytics means that all customer interaction is tracked and measured in real-time. The AR Enterprise platform supports both IOS and Android mobile devices and upcoming wearable technologies.
For more information or to explore working with ImagineAR, please visit www.imagineAR.com .
We encourage you to do your own due diligence and ask your broker if ImagineAR Inc. (cse: IP) is suitable for your particular investment portfolio*.
The Canadian Securities Exchange has neither approved nor disapproved the contents of this press release. This press release may include ‘forward-looking information’ within the meaning of Canadian securities legislation, concerning the business of the Company. The forward-looking information is based on certain key expectations and assumptions made by ImagineAR’s management. Although ImagineAR believes that the expectations and assumptions on which such forward- looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because ImagineAR can give no assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release, and ImagineAR disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
Posted by AGORACOM-JC
at 7:21 AM on Tuesday, December 1st, 2020
Entered into an exclusive Distribution Agreement with United Safety and Survivability Corporation
Under the terms of the agreement, the exclusivity applies to the industries defined as buses, rail and locomotive, subways, ambulances, fire trucks, first responder and military vehicles, with applicable associated facilities in the geography of North America, Australia, and New Zealand.
The exclusivity period is 12 months with a six month mutual renewal option and is based on 5,000 units of BioCloud per annum, on a best efforts basis, to retain exclusivity. Pricing will not be disclosed for industry competitive purposes.
TORONTO, ON / December 1, 2020 / Kontrol Energy Corp.(CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to announce that it has entered into an exclusive Distribution Agreement with United Safety and Survivability Corporation (“United Safety”).
“We are pleased to enter into this agreement with United Safety as we specifically target the important sector of ground transportation with an established and successful global distribution partner,” says Paul Ghezzi, CEO Kontrol. “The United Safety team shares our passion and commitment for creating safe spaces for all.”
Under the terms of the agreement, the exclusivity applies to the industries defined as buses, rail and locomotive, subways, ambulances, fire trucks, first responder and military vehicles, with applicable associated facilities in the geography of North America, Australia, and New Zealand. The exclusivity period is 12 months with a six month mutual renewal option and is based on 5,000 units of BioCloud per annum, on a best efforts basis, to retain exclusivity. Pricing will not be disclosed for industry competitive purposes.
Joseph Mirabile, CEO of United Safety says, “United Safety and Survivability Corporation is committed to delivering the most innovative and reliable solutions that our customers can trust to protect life and property. We are very excited to be sharing the Kontrol BioCloud technology with all of our customers. We see interest and demand for this innovative technology, which can help create safer spaces and help our customers solve many of the challenges they are facing in relation to the impact COVID-19 has on their business.”
About United Safety & Survivability Corporation
United Safety and Survivability Corporation is committed to delivering the most innovative and reliable safety and survivability solutions that our customers can trust to protect life and property. As a global leader in the design and engineering of world-class safety, survivability and technology solutions across a variety of industries and categories, our portfolio of products includes seating for commercial buses, fire trucks, ambulances, military vehicles, motor coaches, rail cars and locomotives. We design and build specialty soldier survivability systems for military vehicles and our revolutionary fire suppression systems are used in school buses, public transit, heavy machinery and more. Our portfolio of products includes Active Air Purification and AEGIS® Microbial Surface Treatment that help to protect the public and operators by eliminating bacteria and viruses from air and surfaces.
BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, offices, retirement homes, hospitals, mass transportation and others.
Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com
BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).
About Kontrol Energy
Kontrol Energy Corp., a Canadian public company, is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol Energy provides a combination of software, hardware, and service solutions to its customers to improve energy management, air quality and continuous emission monitoring.
Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at: www.sedar.com
For further information, contact:
Paul Ghezzi, Chief Executive Officer [email protected] or [email protected] Kontrol Energy Corp., 180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8 Tel: 905.766.0400, Toll free: 1.844.566.8123
Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.
Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.
However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloudTM Analyzer (BioCloudTM) are subject to the risk that the Kontrol BioCloudTM Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.
As the name implies “PropTech” is a combination of two words and stands for “property technology.” As simple as that is, the implementation and importance of PropTech is anything but.
Like every other industry on the planet that is incorporating technology to create greater efficiencies and experiences, the commercial real estate market is no different and is seeing the rapid adoption of;
Artificial Intelligence
Machine learning
Big data
Internet of Things (IoT Sensors)
Cloud computing
To create cost savings by reducing and even eliminating existing costs, create greater efficiencies for the operation and maintenance of real estate assets, as well as, improve the design of new builds.
IMPACT OF COVID-19
The COVID-19 pandemic has served to significantly increased the demand for PropTech in the commercial real estate market as follows:
The need for solutions to get workers back into workplace buildings and offices. Specifically, the need to identify bacteria and viruses in indoor air quality, as well as, the ability to sanitize immediately and effectively.
The need to create even greater cost savings and efficiencies for real estate owners that will continue suffering losses until workers significantly return to the workplace.
WHY UNIVERSAL PROPTECH (UPI:TSXV)?
Whereas many companies are just now trying to capitalize on the opportunities presented in the current and massive future of PropTech, Universal PropTech Inc. (“UPI”) a diversified investment platform delivering healthy building solutions and services for building developers, owners and operators in Canada. More than just lip service, UPI has been successfully delivering its PropTech solutions for years, with revenues over the last 3 years as follows:
2017 – $13.8M
2018 – $13.7M
2019 – $15.9M
Headquartered in Toronto, UPI has offices across Canada including Halifax,Montreal, and Ottawa.
COMPANY HIGHLIGHTS
Used in Federal Government facilities for over 40 years
Provides real estate managers turnkey HVAC Building Controls design, equipment, installation and ongoing operations and maintenance services for Industrial, Commercial, Institutional and Multi-residential customers
Already possesses under-utilized IP in building controls to add in additional monitoring inputs and equipment controls
Diverse revenue streams via products, installations and ongoing
Key strategic partnerships afford the ability to monitor real-time utility meters, key BAS and systems data in a building.
Team has the capability to make sense of this data and apply advanced web tools to make recommendations to fine tune a building, saving from 5% to 15% of a facilities energy spend without capital expenditure
VCI offers the depth and breadth of Building Automation Systems (BAS) knowledge and products from the likes of Siemens and Honeywell to support building automation systems
COVID-19 STRATEGY
As businesses return to the office, property managers must think about the design and safety of their buildings for occupants. Traditional cleaning methods are ineffective at preventing transmission. UV technology is able to sanitize all surfaces free from pathogens. UPI is capitalizing on this opportunity by building and acquiring UV technology as it is the best in the market to administer and integrate it into healthy buildings in Canada.
Posted by AGORACOM-JC
at 4:19 PM on Monday, November 30th, 2020
Q3 2020 revenue increased by 32% over Q2 2020
Adjusted EBITDA of $848,249 reported for Q3 2020 compared to $206,435 for the same quarter in the prior year
Adjusted EBITDA for the nine months ended September 30, 2020 was $1,492,252 compared to $707,263 for the same period in the prior year
Revenue for Q3 2020 was $3.01 million down from $3.27 million in Q3 2019, and year to date totalled $8.05 million down from $10.86 million for the comparative period in the prior year
TORONTO, ON / November 30, 2020 / Kontrol Energy Corp.(CSE:KNR, OTCQB:KNRLF, FSE:1K8) (“Kontrol” or “Company”) a leader smart buildings and smart cities through IoT, Cloud and SaaS technology announces its financial results for the nine months ended September 30, 2020.
A complete set of Financial Statements and Management’s Discussion & Analysis will be filed on SEDAR (www.sedar.com) on November 30, 2020. A call to discuss the financial results has been scheduled for Monday, November 30, 2020 at 4:30pm (EST).
“We had a significant improvement in the third quarter against an ongoing challenging backdrop as businesses continue to deal with the impact of COVID-19,” says Paul Ghezzi, CEO. “In addition, the Company achieved further advancements in the development of the Kontrol BioCloudTM viral and air-borne pathogen detection technology during the third quarter of 2020.”
Highlights
Q3 2020 revenue increased by 32% over Q2 2020
Adjusted EBITDA of $848,249 reported for Q3 2020 compared to $206,435 for the same quarter in the prior year
Adjusted EBITDA for the nine months ended September 30, 2020 was $1,492,252 compared to $707,263 for the same period in the prior year
Revenue for Q3 2020 was $3.01 million down from $3.27 million in Q3 2019, and year to date totalled $8.05 million down from $10.86 million for the comparative period in the prior year
Cash flow from operating activities for the nine months ended September 30, 2020 was $531,675
On August 1, 2020 Kontrol completed the acquisition of New Found Air (“NFA”), a building energy solutions business
Capital management activities during Q3 and subsequent to the quarter have strengthened the balance sheet (see below)
BioCloudTM product development continued at a rapid pace through the third quarter (see below)
Active capital management and balance sheet strengthening
Options and warrants converted into common shares:
Approximately 4.2 million options and warrants were exercised in Q3 and up to date of this press release (average exercise price was $0.73 per share)
Proceeds from options exercise
Q3 2020: $653,000
October 1, 2020 to date of this press release: $224,000
Proceeds from warrants exercise
Q3 2020: $1,404,000
October 1, 2020 to date of this press release: $805,000
Convertible debentures converted into common shares
Approximately 3.2 million common shares were issued in connection with convertible debenture conversions to common shares in Q3 and up to date of this press release
2024 convertible debenture conversion to common shares
Q3 2020: $866,000
October 1, 2020 to date of this press release: $143,000
Conversion price was $0.80 per share
2023 convertible debenture conversion to common shares
Q3 2020: $0
October 1, 2020 to date of this press release: $988,000
Conversion price was $0.50 per share
2020 debenture and 2022 debenture
The Company announced a non-brokered private placement for gross proceeds of $5,800,000, allowing existing holders of 2020 debentures to exchange for 2022 debentures maturing on October 31, 2022
Subscription proceeds are currently being processed in connection with the new 2022 debenture and the extension will be reflected in Q4 and the Company’s December 31, 2020 annual financial statements
Cash position
The Company’s cash balance as at September 30, 2020 was $3,065,995 compared to $644,313 as at December 31, 2019 for a net cash increase of $2,421,682. While proceeds from options and warrants exercise were significant contributors to the net cash increase, management is equally pleased with cash flow that was generated from operating activities of $531,675 for the year to date period.
The Company’s cash balance on day of this press release was approximately $3,800,000.
Q3 2020 and Year to Date Financial Summary
Financial Results
Three months ended
Nine months ended
(unaudited)
Sept 30, 2020
Sept 30, 2019
Sept 30, 2020
Sept 30, 2019
Revenue
$
3,012,386
$
3,266,270
$
8,047,477
$
10,856,816
Gross profit
$
1,601,830
$
1,709,248
$
4,315,650
$
5,465,008
Net loss
$
(193,541
)
$
(692,175
)
$
(1,305,904
)
$
(1,968,653
)
Basic and Diluted EPS
$
(0.01
)
$
(0.02
)
$
(0.04
)
$
(0.07
)
Add for adjusted EBITDA reconciliation:
Amort. and depreciation
$
538,159
$
486,187
$
1,490,017
$
1,355,686
Finance expense
$
250,346
$
272,458
$
816,742
$
779,277
Share based compensation
$
227,274
$
72,686
$
455,386
$
462,576
Acquisition related expenses
$
26,011
$
67,279
$
36,011
$
78,377
Adjusted EBITDA*
$
848,249
$
206,435
$
1,492,252
$
707,263
Kontrol BioCloudTM
The Company has made important progress on its BioCloud TM technology including the receipt of various certifications and filing of trademarks and patents. As part of our ongoing strategy to manage capital and accelerate towards the production of BioCloud the Company is working with various third-party suppliers and contract manufacturers. BioCloud TM product development costs incurred for the current year to date period and up to the time of this press release was approximately $615,000. The Company’s cash position and resources available are sufficient to commence the production of BioCloud TM.
* Adjusted EBITDA is a non-IRFS financial measure. The Company defines Adjusted EBITDA as net income or loss before interest, income taxes, amortization, and depreciation, share based compensation, and acquisition related expenses.
About Kontrol Energy
Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in smart buildings and smart cities through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.
Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com
Posted by AGORACOM-JC
at 4:04 PM on Monday, November 30th, 2020
SPONSOR: Imagine AR Inc. (IP:CSE) (IPNFF:OTCQB) is an Augmented Reality platform that allows businesses to easily launch AR campaigns. Clients Include: NBA Sacramento Kings, Mall of America, AT&T Shape and The Basketball Hall of Fame. ImagineAR and NFL Alumni Academy recently signed a 5 year partnership agreement. The company was selected by Canadian pharmacy chain Shoppers Drug Mart to deliver Immersive AR Conference Experience and if that’s not enough, Imagine AR just signed its second La Liga team to provide AR experiences for fans. Learn More.
The future of live sport – how brands can make an impact with new digital possibilities
We’ve seen the already growing appetite for virtual event counterparts accelerate during the lockdown period.
Our consumer research found that football fans in the UK are now three times more likely to find the prospect of augmented reality (AR) replays and stats exciting, with younger fans more likely to use these technologies in the near future.
By: Mark Melling, Verizon Media
Digital fan experiences like the NFL’s ‘Watch Together’ synchronised livestream are reinventing the way in which consumers enjoy live sports content.
The absence of live sport throughout the COVID-19 pandemic has been felt strongly by fans like me across the globe. From the pre-game rituals, half-time debrief with friends and the atmosphere within the stadium, fans have been missing out on the communal and experience-led aspect of a physical game.
In response to this, we’ve adapted our strategy and looked at new and innovative ways we can elevate the sports fan experience as well as focusing on the entertainment sector more broadly.
We’ve seen the already growing appetite for virtual event counterparts accelerate during the lockdown period. Our consumer research found that football fans in the UK are now three times more likely to find the prospect of augmented reality (AR) replays and stats exciting, with younger fans more likely to use these technologies in the near future.*
This demonstrates how fans are starting to see the value these technologies bring, and so will be more likely to continue using them to enhance the digital experience – even when live sporting events start-up again.
More broadly, the expectation for consumers is that most offline events will have some sort of digital twin and be augmented by tech in some way. We’re already starting to see this amongst the younger generation, with 83% of UK millennials claiming they expect their digital experiences and interactions with brands online to be seamless, innovative, and to enhance what’s happening in the real world.*
The convergence of online and offline
These sorts of insights have been integral in driving our strategy and the platforms we use moving forward – highlighting the importance of exploring the convergence of online and offline.
As part of this, it’s been important for us to consider two key streams: live events with virtual integrations and virtual events with live integrations. The former will be vital for sport as virtual elements can be incorporated to enhance the offline experience.
For example, better quality video streaming, immersive experiences and real-time virtual reality (VR) and AR overlays that will allow viewers to watch the game from multiple angles – including cameras on the players and referees, so that fans can get a point of view shot and feel more involved in the action.
COVID-19 has been instrumental in accelerating demand for these types of experiences. And technology can help to create communal experiences for viewers, even when they are unable to attend the physical venue to watch the game with friends and family under current lockdown restrictions.
As a result, everyone working within the sports industry – from production and distribution to branding and marketing – has had to adjust their strategy and adapt to bringing digital experiences to the forefront. Much of this technology was already in the pipeline but the global pandemic has accelerated plans due to the need to shift to digital overnight.
NFL partnership: ‘Watch Together’
One of the ways we helped to improve the digital fan experience within the sports industry was through our recent partnership with the NFL to launch ‘Watch Together’.
The new platform consists of a co-viewing experience that enables fans to video chat on their phones whilst watching live games in the Yahoo Sports App in the US. Watch Together for NFL Live on Yahoo Sports will give fans the ability to invite up to three family and friends to watch live local and primetime NFL games on their phones through a synchronised livestream, creating an interactive, virtual experience that lets viewers feel like they are watching the game together.
On top of this, the new Yahoo Sports game centre experience offers fans the ability to see graphical replays of key NFL game plays in near real-time using its proprietary Next Gen Stats player tracking data. The NFL is the first launch partner for Watch Together, but it could easily be replicated across the whole sport sector and demonstrates the digital capabilities for consuming live events.
These viewing experiences will be game-changers moving forward, even post-pandemic, and will more intrinsically link the offline and online element of live events. This is an incredible opportunity for brands to test themselves. And marketers should be thinking about their engagement strategies now to establish themselves in this evolving world, taking hold of the unique digital opportunities that are arising.
Supercharging the experience with 5G
This is also where 5G can make a real impact – supercharging the fan experience through rich, real-time and immersive experiences. It will enhance existing technologies and help to cater for the increased demand for online events, while also elevating offline experiences in the future.
For example, e-commerce, social interaction and video replays in between games are all currently available but can be heightened, personalised and delivered in real-time at scale through the connectivity that 5G will enable.
Brands can tap into these opportunities by thinking creatively about ways to bring together the online and offline elements in a meaningful way that will connect with consumers. For live sports – and indeed live entertainment events more broadly – we can expect interactive and immersive experiences to become the norm, with fans looking for new ways to watch the game from their homes.
Brands that do not adapt and help to drive these unique experiences risk being left behind as we hurtle towards a more digitised future.
Posted by AGORACOM-JC
at 3:39 PM on Monday, November 30th, 2020
SPONSOR POST:
WHY KWESST? HERE’S SOME GREAT REASONS
1. KWESST is a leader in defensive technologies that increase the capabilities of soldiers, including those of NATO and its allies.
2. These technologies make a critical difference to soldier safety and effectiveness.
3. The Leadership team experience spans decades and hundreds of millions of dollars in military and homeland security contracts.
4. KWESST develops next-generation systems for forces around the world, with a particular focus on special forces among NATO countries and their allies.
5. KWESST partners with globally recognized equipment manufacturers to integrate its systems into their solutions to create high value-add products for global customers.
UK to invest in AI and cyber as part of major defense spending hike
The UK has announced a massive boost in defense spending — £16.5 billion ($21.8BN) over four years, the biggest such spending bump for 30 years — in what prime minister Boris Johnson has described as a “once in a generation modernization” of the UK’s armed forces and “the end of the era of retreat” on funding for defense.
Overall the UK prime minister said the spending hike will create 40,000 jobs, adding that it will cement the country’s position as the biggest military defense spender in Europe and the second largest in NATO after the US.
Johnson said the focus for investment will be on cutting edge technologies that can “revolutionize” warfare — implying a major role for artificial intelligence and sensor-laden connected hardware in “forging our military assets into a single network designed to overcome the enemy”, as he put it in a statement to parliament, setting out the first conclusions from an the (ongoing) review of security, defense, development and foreign policy.
“A soldier in hostile territory will be alerted to a distant ambush by sensors or satellites or drones instantly transmitting a warning using artificial intelligence to device the optimal response and offering an array of options — from summoning an air strike to ordering a swarm attack by drones, or paralyzing the enemy with cyber weapons,” Johnson told the House of Commons today, speaking via video conference as he continues to self isolate following a coronavirus contact.
“New advances will surmount the old limits of logistics,” he went on, fleshing out the rational for spending on upgrading military technology. “Our warships and combat vehicles will carry directed energy weapons — destroying targets with inexhaustible lasers. And for them the phrase out of ammunition will become redundant.”
“Nations are racing to master this new doctrine of warfare and our investment is designed to place Britain among the winners,” he added.
The review sets out at least £1.5BN extra — and £5.8BN total — spending on military R&D which Johnson said would be “designed to master the new technologies of warfare”.
There will also be a new R&D center set up with a dedicated focus on artificial intelligence, he added.
An RAF Space Command center is also in the works — with the aim of launching British satellites including the UK’s first rocket from Scotland in 2022.
While the airforce will get new fighter system that Johnson specified will incorporate AI and drone technology.
He also confirmed the existence of a National Cyber Force — a joint unit consisting of personnel from the UK’s intelligence agencies and military personnel which runs cyberops targeting terrorism, organized crime and hostile foreign state actors.
He suggested the hike in military spending on emerging technologies will filter down into wider societal tech gains, telling MPs: “The returns will go far beyond our armed forces — from aerospace to autonomous vehicles — these technologies have a vast array of civilian applications, opening up new vistas of economic progress.”
Responding to Johnson’s statement, the leader of the opposition, Keir Starmer, welcomed the announcement of increased spending for defense and the armed forces — but accused the government of issuing another “press release without a strategy” — pointing out that successive Conservative governments have eroded defense spending over the past ten years.
“This is a spending announcement without a strategy. The government has yet again pushed back vital parts of the integrated review and there’s no clarity over the government’s strategic priorities,” said Starmer, going on to query how the spending hike would be funded, given the economic crunch facing the UK as a result of the pandemic — asking whether it will require tax rises or cuts to public spending elsewhere, such as to the international development budget.
Starmer also raised the awkward matter of the Russia report — wondering why Johnson’s government has not acted on the “urgent” national security risks identified there.
The report, by parliament’s intelligence and security committee, found the UK lacks a comprehensive and cohesive strategy to respond to the cyber threat posed by Russia and other hostile states that are deploying online disinformation and influence ops to target democratic institutions and values.
It also sounded the alarm about how much Russian money is finding its way into UK political party coffers.
“The prime minister speaks of tackling global security threats, improving cyber capability — and that is all welcome, and we welcome it — but four months after the intelligence and security committee published its report concluding that Russia posed… an immediate and urgent threat to our national security,” noted Starmer.
Replying, Johnson dodged all Starmer’s questions — branding his criticisms “humbug [that] takes the cake” and opting to attack the Labour leader for having served under the party’s former leader, Jeremy Corbyn, who did not support increasing UK defense spending.
Posted by AGORACOM-JC
at 8:20 AM on Monday, November 30th, 2020
Company reported revenue of $172,889 for the three months ended September 30, 2020, compared with revenue of $234,977 for the three months ended September 30, 2019.
Revenue from SIAscopy ® of $74,286 for the third quarter was 29% higher than the prior year three-month period and more than twice that of the three months ending June 30, 2020.
Revenue from the Company’s therapeutic laser line of $98,603 was a decrease from $177,436 in the prior year period, but $60,180 higher than in the prior three month period.
MedX Health Corp. (“MedX” or “Company”) (TSX-V: MDX) announced its results for the three and nine-months ended September 30, 2020, which are also available on SEDAR ( www.sedar.com ).
The Company reported revenue of $172,889 for the three months ended September 30, 2020, compared with revenue of $234,977 for the three months ended September 30, 2019. Revenue from SIAscopy ® of $74,286 for the third quarter was 29% higher than the prior year three-month period and more than twice that of the three months ending June 30, 2020. Revenue from the Company’s therapeutic laser line of $98,603 was a decrease from $177,436 in the prior year period, but $60,180 higher than in the prior three month period. The Company reported a loss for the three months ended September 30, 2020 of $1,083,772 or $0.01 per share compared with a loss of $577,648, or $0.00 per share for the three months ended September 30, 2019.
The Company reported revenue of $337,885 for the nine months ended September 30, 2020, compared with revenue of $678,886 for the nine months ended September 30, 2019. Revenue from SIAscopy ® of $127,093 was 21% higher than in the first nine months of 2019. Revenue from the Company’s therapeutic laser line of $210,792 for the nine-month period was 63% lower than the $574,069 in the prior year period. The Company reported a loss for the nine months ended September 30, 2020 of $2,532,171 or $0.02 per share, compared with a loss of $2,086,892, or $0.01 per share for the nine months ended September 30, 2019.
“We are pleased that we had strong revenue growth in Q3 compared to Q2, as we more than doubled revenue in each of our product lines,” noted Rob von der Porten, Executive Chairman, and acting CEO. “We made our first shipment of SIAscopy ® units to our Brazilian distribution partner, where they will be deployed on our DermSecure ® platform over the coming months. The sales and marketing team are building a pipeline of international distribution partners for our SIAscopy ® on DermSecure ® telemedicine platform and are experiencing strong interest in the Company’s unique teledermatology platform. While COVID-19 will continue to have an impact on all businesses, it is increasing the interest in telemedicine in general, albeit it is impacting the rate of implementation. While our revenue increased over the second quarter, the loss for the quarter was higher as we built out our sales team, increased marketing efforts, and spent on continued enhancements to our DermSecure ® platform, and as well, we incurred non-cash share-based compensation expense. We remain convinced that we will have long-term, sustainable growth with the MedX DermSecure ® platform and that it is the ‘Gold Standard’ in the teledermatological market space.”
The Company also announces that 800,000 stock options have been granted to Directors. Such options have an exercise price of $0.17 per share, will expire on November 25, 2025, and vest immediately.
MedX also announces it has retained Venture North Capital Inc. (“Venture North”) for strategic marketing, investor relations and capital markets communications services. Venture North will arrange and attend meetings with professional investors, maintain ongoing contact and broaden relationships with the professional investment community on MedX’s behalf.
Under the terms of the agreement, MedX will pay Venture North a monthly fee of $6,000 for ongoing strategic services for an initial six (6) months, after which the relationship will continue on a monthly basis. The agreement may be terminated by MedX or Venture North on 60 days written notice. Venture North will also be granted stock options (the “Options”), totaling up to 900,000 common shares of the Company, which will vest and become exercisable quarterly with 225,000 of the options vesting on each of the dates that are three, six, nine and twelve months from the beginning of the Engagement Period. The Options will be exercisable at a price of $0.17 per share for a period of two years. The appointment and option grant are subject to TSX Venture Exchange approval.
Summary of Recent Announcements:
The following is a summary of recent announcements made by the Company, for which further details can be found under the Company’s profile at www.sedar.com .
MedX Announces Sales Agency Agreement with Ziemer Professional Corp.
On October 28, 2020, the Company announced it had completed a sales agency agreement with the Ziemer Professional Corporation. Ziemer will target its sales efforts within the medical, athletic, and pain management clinic markets. Six new clinics will begin installing the SIAscopy ® on Dermsecure ® telemedicine platform across Ontario and Saskatchewan.
MedX Adds Two New Members to Board of Directors
On October 15, 2020, the Company appointed Anthony Milonas and Wayne Cockburn as Directors of the Company. Mr. Milonas and Mr. Cockburn bring extensive senior management experience working with medical device and health care growth-stage companies, both nationally and internationally. Mr. Milonas is President and CEO of Canadian Orthodontic Partners, a company overseeing a national network of orthodontic practices. Mr. Cockburn is President of The Clinic Network Canada, one of Canada’s largest providers of out-of-hospital pain management services.
MedX Expands Senior Leadership Team
On September 21, 2020, the Company announced the appointment of veteran healthcare industry executive Naman Demaghlatrous as Managing Director, Europe, Middle East & Africa (“EMEA”), and Chantal Ward, RN, as Director, Dermatological Services. Mr. Demaghlatrous brings more than 20 years of experience in the healthcare industry, including roles with companies such as Medtronic, Pediapharm, Johnson & Johnson and Atfal Pharma. Chantal Ward, RN, a Diploma Nurse Graduate with an operating room background, has 20+ years’ experience as a clinical trainer of advanced medical aesthetic equipment and technology.
MedX Announces Management Changes and Increased Focus on SIAscopy® on DermSecure®
On September 9, 2020, the Company announced management changes to enhance its focus on its dermatological services and products including DermSecure ® and SIAscopy ® . Mike Druhan, who has championed SIAscopy ® within the Company for a number of years, has been appointed President, Dermatological Services and Products. Louie Canitano, who has many years of experience in therapeutic laser and light products has been appointed Managing Director, Light Therapy Products.
MedX Announces Closing of Non-Brokered Private Placement
On August 4, 2020, the Company announced that further to the Conditional Approval from the TSX Venture Exchange for a non-brokered Private Placement to accredited investors of up to 16,666,666 units at $0.12 per unit (“Unit”), to raise up to $2,000,000, the closing of a first tranche of that placement has taken place on July 31, 2020, for a total of 2,600,000 units, raising a total of $312,000. Each Unit is comprised of One (1) fully paid common share and One (1) Share Purchase Warrant, exercisable to purchase One (1) further Common Share at the price of $0.20, exercisable for a period of two years from the date of issue. The securities issued will be restricted from trading for four months from the date of issue. In connection with this tranche of the private placement, cash commissions of $24,000 were paid.
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy ® on DermSecure ® telemedicine platform, utilizing its SIAscopy ® technology. SIAscopy ® is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com .
This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company’s limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company’s projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
